McKesson FQ3 revenue $80.9B (+15% YoY), adjusted EPS $7.74 (+12%), raises FY guidance

MCKESSON CORP

2024-Q3 EPS reported $16.39 revenue$232,596,000,000

Revenue $80.9B up 15% YoY; GAAP EPS from continuing ops $4.42 vs $7.65 (down 42%).
Adjusted EPS $7.74 vs $6.90; adjusted earnings $1,032M up 6%.
FY 2024 adjusted EPS guidance raised to $27.25-$27.65 from $26.80-$27.40.
US Oncology Network added Nashville Oncology Associates and SCRI Oncology Partners.
Year-to-date revenue $232.6B (+12%); adjusted EPS $21.24 (+13%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MCKESSON CORP reported the third quarter ended December 31, 2023 results: revenue $80,898, net income $589, EPS $4.42. Guidance raised.

Period: the third quarter ended December 31, 2023
Revenue: $80,898
Net income: $589
EPS: $4.42
Guidance: raised
Result: preliminary results

Exact text from the filing

December 31, 2023. Fiscal 2024 Third Quarter Result Summary Third Quarter Year-to-Date ($ in millions, except per share amounts) FY24 FY23 Change FY24 FY23 Change Revenues $ 80,898 $ 70,490 15 % $ 232,596 $ 207,801 12 % Income from Continuing Operations 2 589 1,078 (45) 2,211 2,776 (20) Adjusted Earnings 2,3 1,032 972 6 2,866 2,697 6 Earnings per Diluted

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

MCKESSON CORP filing history →

Source: SEC EDGAR

accession 0000927653-24-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.